A Phase II Single-arm Open-labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
Phase of Trial: Phase II
Latest Information Update: 16 May 2018
At a glance
- Drugs Omacetaxine mepesuccinate (Primary) ; Quizartinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 May 2018 Status changed from not yet recruiting to recruiting.
- 15 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Oct 2017.